Harmony Biosciences Holdings Inc(HRMY) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 4:57 AM ET (Korea 9/11 17:57)
Full metrics table
| Index | RUT | P/E | 13.32 | EPS (ttm) | 3.09 | Insider Own | 13.91% | Shs Outstand | 58.1M | Perf Week | -4.11% |
| Market Cap | 2.39B | Forward P/E | 9.61 | EPS next Y | 8.52% | Insider Trans | -0.42% | Shs Float | 50.1M | Perf Month | 4% |
| Enterprise Value | 1.95B | PEG | 0.45 | EPS next Q | 1.11 | Inst Own | 95.67% | Short Float | 8.25% | Perf Quarter | 15.84% |
| Income | 0.18B | P/S | 2.49 | EPS this Y | 45.48% | Inst Trans | -3.46% | Short Ratio | 4.94 | Perf Half Y | 42.76% |
| Sales | 0.96B | P/B | 2.39 | EPS next 5Y | 21.26% | ROA | 14.61% | Short Interest | 4.14M | Perf YTD | 9.83% |
| Book/sh | 17.19 | P/C | 3.58 | EPS past 3/5Y | -3% - | ROE | 20.46% | 52W High | -5.5% ($43.49) | Perf Year | 23.76% |
| Cash/sh | 11.47 | P/FCF | 6.74 | Sales past 3/5Y | 25.64% 40.3% | ROIC | 15.93% | 52W Low | 61.05% ($25.52) | Perf 3Y | 7.87% |
| Dividend Est. | - | EV/EBITDA | 7.6 | EPS Y/Y TTM | -0.83% | Gross Margin | 72.94% | Volatility(W/M) | 3.73% 3.17% | Perf 5Y | 13.35% |
| Dividend TTM | - | EV/Sales | 2.03 | Sales Y/Y TTM | 24.25% | Oper. Margin | 24.03% | ATR (14) | 1.32 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.45 | EPS Q/Q | 88.57% | Profit Margin | 18.88% | RSI (14) | 58.2 | Recom | 1.82 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.48 | Sales Q/Q | 30.32% | SMA20 | 2.97% ($39.91) | Beta | 1 | Target Price | $47.36 |
| Payout | - | Debt/Eq | 0.22 | Earnings | 2026/8/4 | SMA50 | 8.41% ($37.91) | Rel Volume | 0.88 | Prev Close | $41.62 |
| Employees | 293 | LT Debt/Eq | 0.14 | EPS/Sales Surpr. | 33.85% 4.19% | SMA200 | 19.65% ($34.35) | Avg Volume(3M) | 0.84M | Price | $41.1 |
| IPO | 2020/8/19 | Option/Short | Yes/Yes | Trades | 11628 | Volume | 736,799 | Change | -1.25% |
Company
HRMY is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A US biopharmaceutical company focused on developing and commercializing treatments for rare neurological disorders. The company has commercialized an oral therapy for sleep-wake disorders such as narcolepsy and is developing a follow-on pipeline targeting additional rare neurological and psychiatric conditions. Operating under a model that combines prescription growth of its commercial product with pipeline advancement, the company is establishing its footprint in the underserved neurological disorders market.
Over the past 1 year, on the higher side
5% below its 1-year high.
HRMY makes money exceptionally well
24.03% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +45.5% this year.
Tap to view numbers
The stock looks undervalued
Trading at 13.3 times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +7.9% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 95.7%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
ABLS 0.03%
PJP 0.03%
ECML 0.02%
XPH 0.02%
PILL 0.01%It ranks #4 in the industry
Based on market cap of $2B.
HRMY $2B PER 13.3
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is HRMY?
HRMY belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of HRMY?
The market cap of HRMY is approximately $2.4B, ranking 1,959 within its sector.
What is the P/E ratio of HRMY?
HRMY has a P/E ratio of approximately 13.3x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for HRMY?
HRMY has recorded a 52-week high of $43.49 and a low of $25.52.
